全球液體切片市場（第七版）

液體切片檢查透過提供一種微創方法來分析循環於生物體液中的腫瘤衍生物質，徹底改變了癌症診斷方式。這種方法為癌症檢測、治療選擇和疾病監測提供了重要的見解，可以補充或取代傳統的組織活檢和影像技術，而這些技術通常存在操作風險和局限性。

Kalorama Information 的 "全球液體活檢市場報告（第七版）" 涵蓋了推動其應用的所有臨床應用，包括早期檢測和篩檢、組織活檢困難時的替代檢測、個人化治療和抗藥性監測、疾病進展和復發監測以及預後評估。

全面的市場分析

"全球液體活檢市場報告（第七版）" 提供了 2025 年至 2030 年全球液體活檢收入的詳細預測，並依以下細分市場進行劃分：

• 依地區劃分： 北美、歐洲、亞洲和世界其他地區（包括區域市場佔有率和成長趨勢）
• 技術類型：基於循環腫瘤DNA (ctDNA)、循環腫瘤細胞 (CTC)、細胞外囊泡和外泌體、多分析物以及其他分析物驅動的方法。對比表格列出了每種方法的優點和限制。
• 依癌症類型劃分： 乳癌、肺癌、大腸癌、卵巢癌、攝護腺癌、泛癌及其他癌症。針對每種適應症提供收入預測和市場佔有率分析。
• 應用領域： 診斷/篩檢、治療指導、微小殘留病灶 (MRD) 檢測和疾病預後。提供市場規模和成長預測以支援分析。

產業洞察與競爭格局

本報告概述了目前已上市和正在研發的部分液體活檢檢測技術，包括基於ctDNA的檢測、基於CTC的平台以及多分析物解決方案。報告比較了這些技術在臨床和研究領域的應用，並分析了監管趨勢。報告的詳細章節提供了技術比較、特定分析物的市場動態以及應用層面的機遇，並包含十幾個表格和圖表，展示了收入預測、市場佔有率和驅動因素。

範圍與方法

本報告涵蓋了全球液體活檢檢測市場。市場數據以檢測公司為單位呈現，涵蓋全球和區域收入。這與大多數KI報告不同，後者通常提供體外診斷（IVD）產品層面的估算。雖然系統和試劑盒並未被排除在外，但它們並非本報告的主要關注點。大多數公司以服務的形式提供這些檢測。

資料基準年為2025年，預測期至2030年。各細分市場的複合年增長率（CAGR）也已提供。

全球液體切片市場的資訊和數據來自廣泛的一手和二手資料。我們訪問了體外診斷醫療器材（IVD）產品製造商、臨床實驗室技術人員和其他產業專家。二手資料包括政府機構、產業協會和獨立出版商的統計和資訊報告及文章。我們也查閱了主要公司的年度報告、公開文件和網站，以識別不斷變化的產品和市場趨勢，評估競爭因素，並加強對整個行業的分析。此外，我們也參考了Kalorama Information和Strategic Directions International (SDi)的部分出版物，以獲取更多背景資訊。 SDi是Kalorama Information的姊妹出版品牌，隸屬於科學與醫學集團。

目錄

第一章：摘要整理

第二章：液體切片技術

• 引言
• 主要液體切片技術

第三章：循環腫瘤DNA (ctDNA) 液體切片

• 引言
• ctDNA在液體活檢中的優勢和局限性
• 基於ctDNA的液體切片檢測
  • Adaptive Biotechnologies
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • LungLife AI
  • Myriad Genetics
  • Natera
  • NeoGenomics
  • OncoDNA
  • Personal Genome Diagnostics (Labcorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
• 基於循環腫瘤細胞 (ctDNA) 的液體活檢檢測的開發
  • BillionToOne
  • Cyclomics
  • Exact Sciences
  • Freenome
  • GRAIL

第四章：循環腫瘤細胞 (CTC) 液體切片

• 引言
• 基於 CTC 的液體活檢檢測開發中的挑戰
• 基於 CTC 的液體活檢檢測
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sc​​ienceces
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
• 基於循環腫瘤細胞 (CTC) 的液體切片檢測（研發中）
  • BioFluidica
  • Epic Sc​​ienceces
  • QCDx

第五章：細胞外囊泡和其他液體切片

• 引言
• 基於細胞外囊泡/其他分析物的液體活檢檢測
  • Biodesix
  • Exosome Diagnostics
  • Mercy BioAnalytics
• 細胞外囊泡液體切片檢測的研發
• 基於囊泡/其他分析物的液體活檢檢測
  • EValuate Diagnostics
  • Insight Molecular Diagnostics（原 OncoCyte）
  • Nanostics
  • VolitionRx

第六章：多分析物液體切片檢測

• 引言
• 多分析物液體切片檢測
  • Biodesix
  • Foundation Medicine（羅氏）
  • LungLife AI
  • NeoGenomics
  • OncoDNA
• 多分析物液體切片檢測的開發
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife人工智慧

第七章：研究性液體切片

• 引言
• 研究性液體切片
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • QIAGEN

第八章：液體切片產業分析

• 引言
• 競爭格局
• 競爭因素
• 主要市場趨勢
• 個人化醫療
• 液體切片市場競爭對手的消失

第九章：液體切片市場

• 市場概覽
• 市場預測

第十章：依分析物劃分的市場

• 整體市場
• 循環腫瘤DNA
• 細胞外囊泡及其他分析物
• 多種分析物

第十一章：依應用劃分的市場

• 概述
• 治療指導與監測
• 診斷/篩檢
• 疾病預後

第十二章：依癌症類型劃分的市場

• 整體市場
• 所有癌症篩檢
• 肺癌
• 攝護腺癌
• 大腸直腸癌
• 乳癌
• 卵巢癌
• 其他癌症

第十三章：公司資料

• 適應性生物技術
• Agena Bioscience, Inc.
• 安格有限公司
• Aspira 女性健康
• Biocartis 集團 NV
• Biodesix
• CellMax Life
• 環基因
• 迪亞卡塔公司
• 史詩科學
• 精確科學
• Freenome, Inc.
• 吉魯皮有限公司
• 聖杯
• Guardant Health, Inc.
• 豪洛捷
• LungLife AI（原 Cynvenio Biosystems）
• MDx健康
• Menarini-Silicon Biosystems，水療中心
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA S.A.
• 個人基因組診斷
• QIAGEN N.V.
  • 無細胞DNA技術
  • CTC Technologies
  • 外泌體和miRNA技術
• Resolution Biosciences（Exact Sciences）
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus AI

Liquid biopsies have transformed cancer diagnostics by offering a minimally invasive method to analyze tumor-derived materials circulating in biological fluids. This approach provides critical insights for cancer detection, therapy selection, and disease monitoring, complementing or replacing traditional tissue biopsies and imaging techniques that often carry procedural risks and limitations.

Kalorama Information's "The Worldwide Market for Liquid Biopsy, 7th Edition" explores the full spectrum of clinical applications driving adoption, including early detection and screening, alternative testing when tissue biopsy is impractical, therapy personalization and monitoring for resistance, disease surveillance for progression and recurrence, and prognostic assessment.

Comprehensive Market Analysis

"The Worldwide Market for Liquid Biopsy, 7th Edition" delivers a detailed forecast of global liquid biopsy revenues from 2025 to 2030, segmented by:

• Geographic Region: North America, Europe, Asia, and Rest of World, with regional market shares and growth trends.
• Technology Type: Circulating Tumor DNA (ctDNA)-based, Circulating Tumor Cell (CTC)-based, Extracellular Vesicle and Exosome-based, Multi-Analyte-based, and other analyte-driven approaches, including comparative tables of advantages and limitations.
• Cancer Type: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and Other Cancers, with revenue forecasts and share analysis for each indication.
• Application: Diagnosis and Screening, Therapy Guidance, Minimal Residual Disease (MRD), and Disease Prognosis, supported by market sizing and growth projections.

Industry Insights and Competitive Landscape

The report profiles selected liquid biopsy tests currently available and in development, including ctDNA-based assays, CTC-based platforms, and multi-analyte solutions. It examines clinical versus research use and regulatory trends. Detailed chapters cover technology comparisons, analyte-specific market dynamics, and application-level opportunities, supported by over a dozen tables and figures illustrating revenue forecasts, market shares, and growth drivers.

Scope and Methodology

This report covers the global market for liquid biopsy testing. The market data pertains to global and regional revenues at the level of testing companies. This differs from most KI reports, which provide estimates at the level of IVD products. While systems and kits are not excluded, they were not the primary focus of this report. Most companies offer these tests as services.

The base year for data is 2025, with forecasts provided through 2030. Compound annual growth rates (CAGRs) are included for each segment.

Information and data on the global liquid biopsy market were obtained from a wide range of primary and secondary sources. Interviews were conducted with manufacturers of IVD products, clinical laboratory technicians, and other industry experts. Secondary sources included statistical and informational reports and articles from government agencies, trade associations, and independent publishing firms. Annual reports, public filings, and websites of leading companies were also reviewed to identify evolving product and market trends, assess competitive factors, and support the overall industry analysis. Selected Kalorama Information and Strategic Directions International (SDi) publications were also consulted for additional background and context. SDi is Kalorama Information's sister publishing brand with the Science and Medicine Group.

Table of Contents

Chapter 1: Executive Summary

• About Kalorama Information
• Scope and Methodology
• Introduction
• Liquid Biopsy Technologies
• Industry Structure
• Liquid Biopsy Market Revenues and Forecast
  • Figure 1-1: Global Market for Liquid Biopsy, 2025-2030 ($ million)
  • Figure 1-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 (%)
  • Figure 1-3: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]

Chapter 2: Liquid Biopsy Technologies

• Introduction
• Major Liquid Biopsy Technologies

Chapter 3: Circulating Tumor DNA (ctDNA) Liquid Biopsy

• Introduction
• Advantages and Limitations of ctDNA in Liquid Biopsy
• ctDNA-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • LungLife AI
  • Myriad Genetics
  • Natera
  • NeoGenomics
  • OncoDNA
  • Personal Genome Diagnostics (Labcorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
• ctDNA-based Liquid Biopsy Tests in Development
  • BillionToOne
  • Cyclomics
  • Exact Sciences
  • Freenome
  • GRAIL

Chapter 4: Circulating Tumor Cells (CTCs) Liquid Biopsy

• Introduction
• Challenges in the Development of CTC-based Liquid Biopsy Tests
• CTC-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
• Selected CTC-based Liquid Biopsy Tests in Development
  • BioFluidica
  • Epic Sciences
  • QCDx

Chapter 5: Extracellular Vesicles and Other Liquid Biopsy

• Introduction
• Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
  • Biodesix
  • Exosome Diagnostics
  • Mercy BioAnalytics
• Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
  • EValuate Diagnostics
  • Insight Molecular Diagnostics (formerly OncoCyte)
  • Nanostics
  • VolitionRx

Chapter 6: Multi-Analyte Liquid Biopsy Tests

• Introduction
• Liquid Biopsy Tests Based on Multiple Analytes
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
• Multiple Analyte-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

Chapter 7: Liquid Biopsy Tests for Research Use Only

• Introduction
• Liquid Biopsy Tests for Research Use Only
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • QIAGEN

Chapter 8: Liquid Biopsy Industry Analysis

• Introduction
• Tiers of Competition
• Competitive Factors
• Significant Market Trends
• Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
• Competitors No Longer in the Liquid Biopsy Market

Chapter 9: Liquid Biopsy Market

• Market Overview
  • Figure 9-1: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]
  • Regional Market Overview
    • Figure 9-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 vs. 2030 (%)
  • Clinical vs. Research Use
• Market Forecast

Chapter 10: Market by Analyte

• Overall
  • Analyte Analysis
    • Figure 10-1: Global Liquid Biopsy Market, by Analyte, 2025 vs. 2030 ($ million) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
    • Figure 10-2: Global Liquid Biopsy Market, Share by Analyte, 2025 vs. 2030 (%) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
• Circulating Tumor DNA
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
  • Circulating Tumor Cells
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Extracellular Vesicles and Other Analytes
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Multiple Analytes
  • Market Overview
  • Revenue Forecast

Chapter 11: Market by Application

• Overview
  • Application Analysis
    • Figure 11-1: Global Liquid Biopsy Market, by Application, 2025 vs. 2030 ($ million) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
    • Figure 11-2: Global Liquid Biopsy Market, Share by Application, 2025 vs. 2030 (%) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
• Therapy Guidance and Monitoring
  • Market Overview
  • Revenue Forecast
  • Minimal Residual Disease (MRD)
  • Market Overview
  • Revenue Forecast
• Diagnosis/Screening
  • Market Overview
  • Revenue Forecast
• Disease Prognosis
  • Market Overview
  • Revenue Forecast

Chapter 12: Market by Cancer Type

• Overall
  • Cancer Type Analysis
    • Figure 12-1: Global Liquid Biopsy Market, by Cancer Type, 2025 vs. 2030 ($ million) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
    • Figure 12-2: Global Liquid Biopsy Market, Share by Cancer Type, 2025 vs. 2030 (%) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
• Pan-Cancer Tests
  • Market Overview
  • Revenue Forecast
• Lung Cancer
  • Market Overview
  • Revenue Forecast
• Prostate Cancer
  • Market Overview
  • Revenue Forecast
• Colorectal Cancer
  • Market Overview
  • Revenue Forecast
• Breast Cancer
  • Market Overview
  • Revenue Forecast
• Ovarian Cancer
  • Market Overview
  • Revenue Forecast
• Other Cancers
  • Market Overview
  • Revenue Forecast

Chapter 13: Company Profiles

• Adaptive Biotechnologies
• Agena Bioscience, Inc.
• ANGLE plc
• Aspira Women's Health
• Biocartis Group NV
• Biodesix
• CellMax Life
• Circulogene
• DiaCarta, Inc.
• Epic Sciences
• Exact Sciences
• Freenome, Inc.
• GILUPI GmbH
• GRAIL
• Guardant Health, Inc.
• Hologic
• LungLife AI (formerly Cynvenio Biosystems)
• MDxHealth
• Menarini-Silicon Biosystems, Spa
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA S.A.
• Personal Genome Diagnostics
• QIAGEN N.V.
  • Cell-free DNA Technologies
  • CTC Technologies
  • Exosome and miRNA Technologies
• Resolution Biosciences (Exact Sciences)
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus AI